title: Nanoparticle incorporation of melittin reduces sperm and vaginal epithelium cytotoxicity.
abstract: Melittin is a cytolytic peptide component of bee venom which rapidly integrates into lipid bilayers and forms pores resulting in osmotic lysis. While the therapeutic utility of free melittin is limited by its cytotoxicity, incorporation of melittin into the lipid shell of a perfluorocarbon nanoparticle has been shown to reduce its toxicity in vivo. Our group has previously demonstrated that perfluorocarbon nanoparticles containing melittin at concentrations <10 µM inhibit HIV infectivity in vitro. In the current study, we assessed the impact of blank and melittin-containing perfluorocarbon nanoparticles on sperm motility and the viability of both sperm and vaginal epithelial cells. We found that free melittin was toxic to sperm and vaginal epithelium at concentrations greater than 2 µM (p<0.001). However, melittin nanoparticles were not cytotoxic to sperm (p = 0.42) or vaginal epithelium (p = 0.48) at an equivalent melittin concentration of 10 µM. Thus, nanoparticle formulation of melittin reduced melittin cytotoxicity fivefold and prevented melittin toxicity at concentrations previously shown to inhibit HIV infectivity. Melittin nanoparticles were toxic to vaginal epithelium at equivalent melittin concentrations ≥20 µM (p<0.001) and were toxic to sperm at equivalent melittin concentrations ≥40 µM (p<0.001). Sperm cytotoxicity was enhanced by targeting of the nanoparticles to the sperm surface antigen sperm adhesion molecule 1. While further testing is needed to determine the extent of cytotoxicity in a more physiologically relevant model system, these results suggest that melittin-containing nanoparticles could form the basis of a virucide that is not toxic to sperm and vaginal epithelium. This virucide would be beneficial for HIV serodiscordant couples seeking to achieve natural pregnancy.
authors.affiliation: Department of Medicine, Division of Cardiology, Consortium for Translational Research in Advanced Imaging and Nanomedicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
authors.forename: Andrew P
authors.initials: AP
authors.lastname: Jallouk
authors.affiliation: Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
authors.forename: Kelle H
authors.initials: KH
authors.lastname: Moley
authors.affiliation: Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
authors.forename: Kenan
authors.initials: K
authors.lastname: Omurtag
authors.affiliation: Department of Medicine, Division of Cardiology, Consortium for Translational Research in Advanced Imaging and Nanomedicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
authors.forename: Grace
authors.initials: G
authors.lastname: Hu
authors.affiliation: Department of Medicine, Division of Cardiology, Consortium for Translational Research in Advanced Imaging and Nanomedicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
authors.forename: Gregory M
authors.initials: GM
authors.lastname: Lanza
authors.affiliation: Department of Medicine, Division of Cardiology, Consortium for Translational Research in Advanced Imaging and Nanomedicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
authors.forename: Samuel A
authors.initials: SA
authors.lastname: Wickline
authors.affiliation: Department of Medicine, Division of Cardiology, Consortium for Translational Research in Advanced Imaging and Nanomedicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
authors.forename: Joshua L
authors.initials: JL
authors.lastname: Hood
mesh_terms: D002461:Cell Line, Transformed; D004847:Epithelial Cells / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008555:Melitten / Q000494:pharmacology*; D053758:Nanoparticles; D013094:Spermatozoa / Q000187:drug effects*; D014621:Vagina / Q000187:drug effects*
chemical_list: D008555:Melitten
references.citation: AIDS. 2010 Jan 16;24(2):163-87
references.pmid: 20010071
references.citation: J Clin Invest. 2009 Sep;119(9):2830-42
references.pmid: 19726870
references.citation: Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):859-64
references.pmid: 1391524
references.citation: Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011 Jul-Aug;3(4):389-99
references.pmid: 21506290
references.citation: Circulation. 2003 Nov 4;108(18):2270-4
references.pmid: 14557370
references.citation: Lab Invest. 2009 Nov;89(11):1317-28
references.pmid: 19786948
references.citation: Nano Lett. 2008 Apr;8(4):1131-6
references.pmid: 18302330
references.citation: J Biochem Biophys Methods. 2000 Jul 10;44(1-2):1-30
references.pmid: 10889273
references.citation: Antivir Ther. 2013;18(1):95-103
references.pmid: 22954649
references.citation: AIDS. 2010 Aug 24;24(13):1975-82
references.pmid: 20679759
references.citation: Science. 2010 Sep 3;329(5996):1168-74
references.pmid: 20643915
references.citation: J Androl. 1997 Mar-Apr;18(2):151-8
references.pmid: 9154509
references.citation: J Reprod Immunol. 2011 Dec;92(1-2):1-7
references.pmid: 22015004
references.citation: Expert Opin Drug Deliv. 2010 Jan;7(1):37-48
references.pmid: 20017659
references.citation: Nat Rev Drug Discov. 2002 Dec;1(12):977-85
references.pmid: 12461519
references.citation: Hum Reprod. 1996 Mar;11(3):627-32
references.pmid: 8671281
references.citation: Reprod Biol Endocrinol. 2004 Mar 10;2:10
references.pmid: 15012833
references.citation: Cochrane Database Syst Rev. 2011 Jan 19;(1):CD008498
references.pmid: 21249711
references.citation: Lancet. 2010 Oct 16;376(9749):1329-37
references.pmid: 20851460
references.citation: J Exp Med. 2009 Nov 23;206(12):2717-33
references.pmid: 19858326
references.citation: Biochim Biophys Acta. 1990 May 7;1031(2):143-61
references.pmid: 2187536
references.citation: Hum Reprod Update. 2006 Jan-Feb;12(1):23-37
references.pmid: 16272225
references.citation: Mol Pharm. 2013 Nov 4;10(11):4168-75
references.pmid: 24063304